Affimed (NASDAQ:AFMD) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
This table compares Affimed and Intec Pharma’s net margins, return on equity and return on assets.
This is a breakdown of recent ratings and target prices for Affimed and Intec Pharma, as reported by MarketBeat.com.
Affimed presently has a consensus target price of $5.23, indicating a potential upside of 54.40%. Intec Pharma has a consensus target price of $13.30, indicating a potential upside of 140.94%. Given Intec Pharma’s higher possible upside, analysts plainly believe Intec Pharma is more favorable than Affimed.
Affimed has a beta of